Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/NMPA/Amisulpride Tablets

Approved

化学药品

Amisulpride Tablets

齐鲁制药有限公司🇨🇳 National Medical Products Administration

Approval Date: Apr 24, 2020
Approval ID: 7Leaey0UXC8
Company: 齐鲁制药有限公司
Type: 化学药品

Approval Details

Approval Id: 7Leaey0UXC8
Approval Number: 国药准字H20113231
Generic Name: 氨磺必利片
Generic Name En: Amisulpride Tablets
Brand Name: 帕可
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 0.2g
Reg Date: 2020-04-24
Company Name: 齐鲁制药有限公司
Production Company Name: 齐鲁制药有限公司(药品上市许可持有人)
Production Company Address: 山东省济南市高新区旅游路8888号
Company Detail Path: /organization/qi-lu-zhi-yao-you-xian-gong-si

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Apr 24, 2020

Approval ID

7Leaey0UXC8

Type

化学药品

Back to NMPA Approvals

帕可 - NMPA Drug Approval Details